
Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week
Keywords: AE; adverse event; ARR; annualized relapse rate; CDW; confirmed disability worsening; CI; confidence interval; DMT; disease-modifying therapy; EDSS; Expanded Disability Status Scale; IFN; interferon; IM; intramuscular; IPD; individual patient data; NEDA;